FDA approves sNDA for Xeljanz

Share this article:

Pfizer said yesterday that FDA approved a supplemental New Drug Application (sNDA) to update the label of RA pill Xeljanz to include radiographic data from two Phase-III studies, ORAL Scan and ORAL Start.

The updated US label will now include the radiographic response data from ORAL Scan (Study IV) at 6 months and ORAL Start (Study VI) at 6 and 12 months. These studies evaluated the effect of the drug on the progression of structural joint damage.

The ORAL Start study showed that Xeljanz was superior to methotrexate by a statistically significant margin in inhibiting progression of structural joint damage, while the ORAL Scan study showed Xeljanz reduced progression of structural joint damage more than placebo. 

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Apple selfies spur diabetes donations

Jazz apples has launched a Crunch to Contribute campaign to raise money for one of two diabetes associations.

Baxter seeks Cambridge, Mass. HQ

Illinois may be tempted to offer tax incentives for the firm to stay put.

FDA wants Alexion to clean up

FDA inspectors have cited the manufacturer of the rare-disease drug Soliris (eculizumab) for poor manufacturing practices.